Stephen MacMillan: Yes, we worry all the time. But at the end of the day, we’ve also built an incredible sales force that has partnered both with the labs, but also with the clinicians. And our assays have proven themselves over time as well as do not underestimate the workflow advantages of our Panther system. And so, there’s a lot of people that can talk a good game and especially let’s face it. There were so many startups that all were working on stuff and then they got money in COVID time and they start talking about all their women’s health assays. And it’s an interesting little landscape right now. So we never take anybody for granted. We face some very formidable competitors, but we always have and we will continue to and we frankly think we continue to innovate things like BB/CV. We continue to bring new assays and new tests and new education to our customers. And that continues to provide strength for us.
Tim Daley: All right. And I appreciate that. And then one for Karleen. So Surgical, great to hear about the performance outside of the legacy products and appreciate the detail on the growth drivers this year. But could you kind of give us a bit more quantified detail about growth ranges here across the various buckets, so kind of the legacy products versus the new in house developed versus kind of the recent acquisitions, any additional kind of above below ranges or anything like that you could provide? And thank you.
Karleen Oberton: Yes. What I would say is dollar contribution is probably evenly split between the legacy platform and affluent our new innovative and then the acquisitions. But certainly, the percentage growth rate is much higher than the acquisitions building off a smaller base. But at the end of the day, I think the key takeaway is, there’s not just one growth driver, there’s multiple growth drivers that are driving the success of that business.
Operator: And our next question will come from Tejas Savant with Morgan Stanley.
Tejas Savant: Hey, guys. Good evening and thanks for the time here. Maybe I’ll start with a couple on some of the recent deals for you, Steve. On Mobidiag, can you just remind us again where things stand in terms of — I think you had said there’s an entry buildup underway ahead of the launch. How big do you think the revenue opportunity could be in fiscal 2023? And then similarly, you highlighted Biotheranostics a couple of times today and obviously, they’ve got into guidelines. They have the recent data from December as well. How big do you see this opportunity becoming for you, perhaps not this year, but a couple of years out?
Stephen MacMillan: Sure. I think on Mobi, Mobi will still be pretty small this year. Mobi will hit its stride ultimately when bring it to the U.S. which is still several years away. But we love the platform we have there. On Biotheranostics, it’s still very small penetration. So the reality is, clearly, it’s going to be probably potentially a few hundred million, we’re not sure at this point, never great at. When you’re creating new markets, it’s always really hard because when you go back eight years ago, people ask me, could MyoSure someday be the size of NovaSure. And at that point in time, it was hard to picture that. And today, MyoSure is way bigger than NovaSure. So I think this magic that we have where we really are creating and building markets, it’s sometimes hard to fully put a number on it other than to see, we think there’s a lot of runway here, a lot.
